News

What's going on here?BofA Securities just got more cautious on Alnylam’s heart-drug story, trimming its peak sales view to $11.8 billion and cutting its price…

Anselamimab therapy is associated with improved all-cause mortality (ACM) and reduced cardiovascular hospitalizations (CVHs) in patients with kappa immunoglobulin…

ExtractTransthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure with a complex and heterogeneous disease course. Accurate…

AbstractBackground: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy and an increasingly recognized cause of heart failure. With…

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market was valued at USD 5.85 billion in 2025 and is projected to reach USD 64.09 billion by 2033, growing…

Amvuttra (vutrisiran) rapidly and consistently reduces blood levels of transthyretin (TTR), the disease-causing protein in hereditary transthyretin amyloidosis with…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative disease of the myocardium. Early diagnosis is essential for the…

AbstractBackground: In low-flow, low-gradient aortic stenosis (LFLG AS), restricted aortic valve opening may represent either fixed valvular obstruction or flow-…

The Cardiac Amyloidosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into cardiac amyloidosis therapeutics currently undergoing…

The incidence of polyneuropathy (PN) related to transthyretin amyloidosis (ATTR) among patients with TTR-mediated amyloid cardiomyopathy (ATTR-CM) in…